No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PSIL ADVISORSHARES PSYCHEDELICS ETF
- 1.255
- +0.015+1.21%
Close Apr 26 16:00 ET
1.255High1.230Low
1.255High1.230Low24.72KVolume1.240Open1.240Pre Close30.80KTurnover0.44%Turnover Ratio--P/E (Static)5.60MShares2.24452wk High--P/B7.03MFloat Cap1.20052wk Low0.00Dividend TTM5.60MShs Float10.471Historical High0.24%Div YieldTTM2.02%Amplitude1.200Historical Low1.246Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
Express News | Vistagen Therapeutics Inc: Ph15 Was Safe and Well-Tolerated With an Adverse Event Profile Similar to Placebo
Express News | Vistagen Therapeutics Inc: Ph15 Nasal Spray Demonstrates Statistically Significant Efficacy Versus Placebo and Caffeine
Express News | Vistagen Announces Positive Results From Phase 2a Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen Announces Positive Results From Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants.
Comments
$ATAI Life Sciences(ATAI.US$
$Cybin(CYBN.US$$Enveric Biosciences(ENVB.US$$Mind Medicine(MNMD.US$$Seelos Therapeutics(SEEL.US$$COMPASS Pathways(CMPS.US$$ADVISORSHARES PSYCHEDELICS ETF(PSIL.US$ building up short positions. The whole sector has taken a huge smack regardless of the fda approvels, Cybin having a clinic in New York. Envb having its Psy-ai. Seelos is up big without any indication of why. Mind med is down, started more studies on mdma and lsd. Get ready and load up. Things are looking strange.
$Cybin(CYBN.US$$Enveric Biosciences(ENVB.US$$Mind Medicine(MNMD.US$$Seelos Therapeutics(SEEL.US$$COMPASS Pathways(CMPS.US$$ADVISORSHARES PSYCHEDELICS ETF(PSIL.US$ building up short positions. The whole sector has taken a huge smack regardless of the fda approvels, Cybin having a clinic in New York. Envb having its Psy-ai. Seelos is up big without any indication of why. Mind med is down, started more studies on mdma and lsd. Get ready and load up. Things are looking strange.
10
1
$ADVISORSHARES PSYCHEDELICS ETF(PSIL.US$ what even are those sell orders?
$ADVISORSHARES PSYCHEDELICS ETF(PSIL.US$ hey everyone! Let's get the trip started
1
Read more
PYUN970IHaveChosen : IKR WTF! I have been watching and holding ATAI/CMPS/CYBN! ATAI is
! Now check the MUSK Depression FIGHT! (I’d depressed if I couldn’t figure out how to spend all that money as well, LMAO) nothing wrong with some Microdosing!